Efficacy assessments included @ % improvement in American College of Rheumatology ( ACR@ ) response , C-reactive-protein-based , @-joint-count Disease Activity Score ( DAS@-CRP ) response , @ % improvement in Psoriasis Area and Severity Index ( PASI@ ) scores , and PsA-modified Sharp/van der Heijde scores ( SHSs ) .